Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2004

View Archived Issues

First report of selective epsilon opioid receptor agonist

Role of oleamide and anandamide in food intake and sexual behavior in rats

Cephalon completes acquisition of CIMA Labs

Novel parenteral carbapenem against multidrug-resistant bacteria

Endo closes agreement to market Frova in North America

Macugen NDA accepted for review

Karo Bio continues progress across several research areas

Bivalent ligand selectively targets spinal cord delta-kappa heterodimers

Multichannel blocker attenuates arrhythmia and cardiac failure

Eisai presents novel SERM derivatives

Selective prostaglandin D2 receptor antagonist for the treatment of allergic rhinitis

Arena claims new 5-HT2A receptor modulators and their therapeutic use

New HGF modulators prepared and tested at Angion Biomedica

Novel PDE4 inhibitors in early development at Almirall Prodesfarma

Artesian researchers claim dual beta-AR/PDE3 inhibitors

New EGFR inhibitors identified by Ariad scientists

Two series of histamine H3 antagonists/inverse agonists designed at GSK

Dual NK1 antagonists/5-HT reuptake inhibitors presented by AstraZeneca

New phase I/II study of CG-7870 plus Taxotere for prostate cancer

Antigen Express and Massachusetts General Hospital collaborate in HIV

MedImmune advances IL-9 monoclonal antibody into new phase I study

SBIR grant supports development of improved interferon beta analogues

BioPort IND accepted for anthrax immunity stimulating molecule

Taxotere approved for early-stage breast cancer

Viventia Biotech and Acceptys enter option agreement for anticancer antibodies

Protox Therapeutics retains CTBR for preclinical testing of PSA-PA1

Abbott presents results of a neuronal nicotinic receptor agonist with analgesic activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...